TB-500 Dosage Guide: Systemic vs Local, Protocols & Cycle Length
TB-500 (Thymosin Beta-4 fragment) is the systemic healing counterpart to BPC-157. Loading dose is 2-2.5mg twice weekly. Unlike BPC-157, it does not need to be injected near the injury -- its mechanism works systemically regardless of injection site.
Quick Reference
Loading dose
2-2.5mg
Loading freq.
2x weekly
Maintenance
2mg 1x weekly
Half-life
12-24 hours
Category 2 (PCAC review July 23, 2026). Full registry →
How Does TB-500 Work?
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring peptide found in high concentrations at sites of tissue injury. Its primary mechanism is the regulation of actin -- the structural protein that drives cell shape, movement, and migration.[1]
By upregulating actin polymerization, TB-500 accelerates the migration of stem cells, endothelial cells, and keratinocytes to injury sites.[2] This makes it particularly effective for structural repairs -- tendons, ligaments, cardiac tissue, and muscle. Phase 2 clinical trial data exists for cardiac applications, giving it a stronger evidence base than most research peptides.[4]
Why it is systemic by nature: Actin regulation and cell migration are body-wide processes that distribute through circulation. Unlike BPC-157 which drives VEGF upregulation locally, TB-500's mechanism reaches all tissues regardless of injection site. Injecting near the injury does not improve efficacy -- abdomen SubQ is equally effective and far simpler.
What Is the Right TB-500 Dosage?
TB-500 protocols use a loading phase followed by an optional maintenance phase. This reflects its longer half-life (12-24 hours) and how it accumulates in tissue over repeated dosing.
Loading Phase (weeks 1–4 to 1–6)
Saturate tissue and drive acute healing.
Dose
2-2.5mg
Frequency
2x weekly
Duration
4-6 weeks
Maintenance Phase (optional, weeks 5–12+)
Sustain healing progress for chronic or severe injuries.
Dose
2mg
Frequency
1x weekly
Duration
4-8 weeks
Should TB-500 Be Injected Near the Injury or Systemically?
This is the key practical difference between TB-500 and BPC-157 -- and the most common point of confusion.
TB-500: Always Systemic
- •SubQ abdomen or thigh -- location does not matter
- •Actin regulation distributes through circulation
- •No benefit to injecting near the injury site
- •Standard insulin syringe, abdomen, twice weekly
- •Simpler and just as effective as any local injection
BPC-157: Local for Injuries
- •Best injected near the injury site for musculoskeletal repair
- •VEGF upregulation and angiogenesis are localized
- •Local concentration matters for tissue-level healing
- •Dosed daily due to short 4-6 hour half-life
- •Systemic also works for gut healing
In the Wolverine Protocol: BPC-157 goes near the injury (local VEGF growth) while TB-500 goes in the abdomen (systemic cell migration). Two different stages of the healing cascade, neither redundant.
TB-500 vs BPC-157: Key Differences
| TB-500 | BPC-157 | |
|---|---|---|
| Mechanism | Actin regulation, cell migration | VEGF upregulation, angiogenesis |
| Effect scope | Systemic | Local (+ some systemic) |
| Best injection site | Abdomen SubQ (anywhere) | Near the injury site |
| Half-life | 12-24 hours | 4-6 hours |
| Dosing frequency | 2x weekly (loading) | 1-2x daily |
| Evidence base | Phase 2 cardiac trial data | 50+ animal/human studies |
| Regulatory status | Category 2 (PCAC July 23, 2026) | Category 2 (PCAC July 23, 2026) |
| Gut healing | Limited | Strong (especially oral arginate) |
| Best use case | Systemic injury, inflammation | Local injury, gut, nerve |
See the BPC-157 Dosage Guide for full BPC-157 protocols and dosing tables.
TB-500 Dosing Reference by Indication
| Indication | Loading | Maintenance | Route | Cycle |
|---|---|---|---|---|
| Acute Tendon / Ligament Injury | 2.5mg 2x weekly | 2mg 1x weekly | SubQ abdomen | Loading 4-6w + maint. 4-8w |
| Chronic Tendinopathy | 2mg 2x weekly | 2mg 1x weekly | SubQ abdomen | 8-12 weeks |
| Muscle Tear / Strain | 2.5mg 2x weekly | 2mg 1x weekly | SubQ abdomen | 4-6 weeks |
| Joint / Cartilage Repair | 2mg 2x weekly | 2mg 1x weekly | SubQ abdomen | 8-12 weeks |
| General Anti-Inflammatory | 2mg 2x weekly | 2mg 1x weekly | SubQ abdomen | 4-6 weeks |
| Wolverine Stack (+ BPC-157) | 2.5mg TB-500 2x wk + 500mcg BPC 2x daily | 2mg TB-500 1x wk + 250mcg BPC 1x daily | SubQ (can mix) | 6-8 weeks |
Doses reflect community research protocols, not FDA-approved clinical guidelines. TB-500 is not approved for human use.
How to Reconstitute TB-500
TB-500 typically comes as lyophilized powder in 2mg or 5mg vials. Add bacteriostatic water slowly along the vial wall. Do not shake -- swirl gently. Store refrigerated, stable 4-6 weeks after reconstitution.
Common example: 2mg vial + 1ml BAC water
Concentration
2mg/ml
1ml in 2mg vial
2mg dose
100 units
U-100 insulin syringe
5mg vial @ 2ml BAC
50u = 1.25mg
Adjust per dose target
The Wolverine Protocol: Stacking TB-500 with BPC-157
The most widely referenced repair stack. TB-500 (systemic) and BPC-157 (local) address tissue injury from two complementary angles simultaneously -- different mechanisms, different stages of the healing cascade.
TB-500 (systemic)
2-2.5mg, 2x weekly
SubQ abdomen. Actin regulation, cell migration, anti-fibrotic.
BPC-157 (local)
250-500mcg, 2x daily
SubQ near injury. Local VEGF, angiogenesis, new vessel formation.
Why they work better together: BPC-157 drives vascular growth locally. TB-500 drives migration of repair cells systemically. Neither mechanism overlaps -- they target different stages of the healing cascade.
Frequently Asked Questions
What is the standard TB-500 dosage?
Loading: 2-2.5mg twice weekly for 4-6 weeks. Maintenance: 2mg once weekly. TB-500's 12-24 hour half-life means daily dosing is not necessary, unlike BPC-157.
Should TB-500 be injected near the injury?
No. TB-500 works systemically through actin regulation and cell migration that distribute via circulation. Inject SubQ in the abdomen regardless of injury location -- proximity to the site does not improve efficacy.
Does TB-500 require post-cycle therapy?
No. TB-500 does not suppress the HPTA, does not affect testosterone, and is not androgenic. No PCT needed.
Can TB-500 and BPC-157 be mixed in the same syringe?
Yes. Both store in bacteriostatic water and are compatible. Draw BPC-157 first, then TB-500. Use immediately. Standard in the Wolverine Protocol.
TB-500 Legal Status: July 23, 2026
Category 2 (restricted from 503A compounding). PCAC reviews July 23, 2026 alongside BPC-157 for potential reclassification to Category 1.
References
- [1]Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta-4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
- [2]Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. PMID 20536467.
- [3]Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID 10469335.
- [4]Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
Citations are provided for informational context. This article does not reproduce copyrighted content from these sources.
Share this article